Shopping Cart
- Remove All
Your shopping cart is currently empty
EGFR kinase inhibitor 6 (Compound 4b) is an orally active epidermal growth factor receptor (EGFR) kinase inhibitor with an IC50 of 24.34 μM. It induces apoptosis and demonstrates anticancer and anti-inflammatory properties, exhibiting low toxicity with an LD50 range of 500-2000 mg/kg.

| Description | EGFR kinase inhibitor 6 (Compound 4b) is an orally active epidermal growth factor receptor (EGFR) kinase inhibitor with an IC50 of 24.34 μM. It induces apoptosis and demonstrates anticancer and anti-inflammatory properties, exhibiting low toxicity with an LD50 range of 500-2000 mg/kg. |
| In vitro | EGFR kinase inhibitor 5 (0-80 μM, 72 h) hinders the migration of A549 cancer cells and reduces the viability of A549, MCF7, and HCT116 cancer cells, with IC₅₀ values of 21.06, 29.25, and >60 μM, respectively. |
| In vivo | The kinase inhibitor EGFR 6 (13.37 mg/kg, oral, 15 days) demonstrates anti-inflammatory activity in a carrageenan-induced rat paw edema model while showing a low propensity to cause ulceration and lipid peroxidation. |
| Formula | C21H16ClN3OS2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.